Brief: Kintara Therapeutics Receives Study May Proceed Letter From The FDA For REM-001
09/08/2022 16:25
Aug 9 (Reuters) - Kintara Therapeutics Inc KTRA.O :
* KINTARA THERAPEUTICS RECEIVES STUDY MAY PROCEED LETTER FROM THE FDA FOR
REM-001
FOR CUTANEOUS METASTATIC BREAST CANCER
Source text for Eikon: ID:nPn8m2prza
Further company coverage: KTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.